Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group.
Children with partial-onset seizures, with or without secondary generalization, participating in a double-blind, placebo-controlled trial of topiramate (TPM) as adjunctive therapy were eligible to participate in an open-label, long-term extension study.



A total of 83 children (mean age, 9 years) continued long-term open-label TPM therapy in which the dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted according to clinical response (mean TPM dosage, 9 mg/kg/day).



Seizure frequency over the last 3 months of therapy was reduced > or =50% in 57% of children; 14% of children were seizure-free > or =6 months at the last visit. During treatment periods up to 2 1/2 years (mean, 15 months), 6% of children discontinued because of treatment-emergent adverse events; 13% discontinued because of inadequate seizure control.



From these findings, TPM is well tolerated and provides long-term seizure control in children with partial-onset seizures.
Ritter
F
F
Minnesota Epilepsy Group, P.A., St. Paul 55102, USA.
Glauser
T A
TA
Elterman
R D
RD
Wyllie
E
E
D000293:Adolescent; D000367:Age Factors; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004828:Epilepsies, Partial / Q000175:diagnosis / Q000188:drug therapy*; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010919:Placebos; D012720:Severity of Illness Index; D000077236:Topiramate; D016896:Treatment Outcome
D000927:Anticonvulsants; D010919:Placebos; D000077236:Topiramate; D005632:Fructose